On the stock market since 2021, it operates in the everyday-essentials business. It has 2 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 28% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 18% a year on average.
Sales run at $689K a year. A small number, but proof the product has real buyers.
A loss of $197K against $689K in annual sales.
The stock sits at $0.0006. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, GHMP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GHMP is a high-risk stock — not yet profitable, and its future rides on its product catching on.